246 Nephrotic Syndrome in patient with Lyme Disease: Case Report

2021 ◽  
Vol 77 (4) ◽  
pp. 644-645
1990 ◽  
Vol 74 (6) ◽  
pp. 325-327 ◽  
Author(s):  
D J Kauffmann ◽  
G P Wormser

1994 ◽  
Vol 18 (2) ◽  
pp. 166-171 ◽  
Author(s):  
H. W. Horowitz ◽  
K. Sanghera ◽  
N. Goldberg ◽  
D. Pechman ◽  
R. Kamer ◽  
...  

2019 ◽  
Vol 11 (3) ◽  
Author(s):  
Iman Dabiri ◽  
Ahmet Z. Burakgazi

Ocular manifestations of Lyme disease (LD) remain a rare feature of the disease, but it may present a wide range of clinical presentations with different combinations. LD related optic neuritis or cranial nerve (CN) six palsy have been reported in the literature. However, this is the first case report of simultaneous involvement of CN 2 and CN 6 in a patient with LD. The diagnosis of LD can be challenging and initial laboratory tests can be a false negative. It is paramount important to repeat the diagnostic test if clinical suspicious is ongoing. With this case, we aim to increase awareness of clinicians for possible ocular manifestations of LD and its complex diagnostic process.


Author(s):  
James Palmieri ◽  
Scott King ◽  
Arben Santo ◽  
Matthew Case

1999 ◽  
Vol 11 (2) ◽  
pp. 89-95 ◽  
Author(s):  
James E Stottlemyer O.D

2020 ◽  
Vol 4 (2) ◽  
pp. 150-1523
Author(s):  
Joshua Lowe ◽  
James Pfaff

Introduction: Facial diplegia, a rare variant of Guillain-Barré syndrome (GBS), is a challenging diagnosis to make in the emergency department due to its resemblance to neurologic Lyme disease. Case report: We present a case of a 27-year-old previously healthy man who presented with bilateral facial paralysis. Discussion: Despite the variance in presentation, the recommended standard of practice for diagnostics (cerebrospinal fluid albumin-cytological dissociation) and disposition (admission for observation, intravenous immunoglobulin, and serial negative inspiratory force) of facial diplegia are the same as for other presentations of GBS. Conclusion: When presented with bilateral facial palsy emergency providers should consider autoimmune, infectious, idiopathic, metabolic, neoplastic, neurologic, and traumatic etiologies in addition to the much more common neurologic Lyme disease.


2018 ◽  
Vol 11 (3) ◽  
pp. e5
Author(s):  
Manish Sheth ◽  
Shashita Inamdar ◽  
Newshaw Karkhanehchin ◽  
Brandyn Roach ◽  
Madison Walsh ◽  
...  

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Zhour El Ouafi ◽  
Clovis Mugnier ◽  
Robin Jeannet ◽  
Clément Danthu ◽  
Marion Duval ◽  
...  

Abstract Background Thymomas have been associated with a broad spectrum of autoimmune diseases. Minimal change disease (MCD) is the most frequent pathological lesion reported. Pathophysiological mechanisms involved in secondary MCD, and linking MCD to thymoma are not yet fully explained, although the hypothesis of T cell dysfunction has been suggested. The fundamental therapeutic principles are steroids and surgical treatment of thymoma, but failures and relapses often require immunosuppressant combinations. Case presentation A 62-year-old female was admitted in our unit for a nephrotic syndrome associated with a thymoma. The diagnosis of thymoma associated MCD was confirmed by kidney biopsy. After surgical resection of the thymoma and steroid therapy, no remission was observed. Immunosuppressive therapy was then intensified with introduction of rituximab. Here, we report a steroid-resistant nephrotic syndrome secondary to MCD associated thymoma, which achieved complete remission after rituximab therapy. To the best of our knowledge, this is the first report of the use and efficacy of rituximab therapy in this pathology. Conclusions Our case report suggests that primary and secondary MCD may share similar pathophysiological mechanisms. It does not allow us to draw any conclusions about the mechanism of action of rituximab, but we believe this report argues for the safety and efficacy of rituximab use in thymoma-associated MCD, and therefore constitutes a rationale for future studies.


Sign in / Sign up

Export Citation Format

Share Document